PIK3CA and malignant pleural mesothelioma: To our knowledge, only one study previously focused on combinations of ARQ 197 (MET inhibitor) and NVP-BEZ235 (dual PI3K/mTOR inhibitor) in malignant pleural mesothelioma, suggesting a benefit of this combinatorial approach [51].